William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company’s shares opened today at $21.87.
Prasad commented:
“We view 2019 as a pivotal year for the company as it determines the optimal dosing, preconditioning, and persistence strategy to use in later-stage clinical trials targeting NKG2D.”
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 19.4% and a 59.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Celyad with a $46 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $37.50 and a one-year low of $15.36. Currently, Celyad has an average volume of 6,760.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
